Compounds > mifepristone
Page last updated: 2024-08-23

mifepristone and mdv 3100

mifepristone has been researched along with mdv 3100 in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (50.00)24.3611
2020's4 (50.00)2.80

Authors

AuthorsStudies
Cen, S; Cui, X; He, Y; Huang, C; Li, X; Liu, M; Wu, M; Xie, Y; Zhang, R; Zhou, J1
Chai, X; Duan, M; Fu, W; Gong, Z; Hou, T; Lei, Y; Li, D; Liao, J; Pang, J; Shan, L; Sheng, R; Tang, C; Tang, Q; Wang, X; Xu, X; Zhang, M1
Cai, Y; Conzen, SD; Isikbay, M; Kach, J; Kregel, S; Otto, K; Szmulewitz, RZ; Vander Griend, DJ1
Göös, H; Lampinen, RE; Lempiäinen, JK; Niskanen, EA; Palvimo, JJ; Varjosalo, M; Vuoti, KM1
Kucuk, O; Li, X; Mamouni, K; Wu, D; Yang, Y1
El-Naggar, AK; Ferrarotto, R; Lin, SH; Mitani, Y; Pytynia, KB1
Alumkal, J; Bayani, N; Bucher, E; Carroll, P; Chauchereau, A; Chiotti, K; Derrick, D; Feiler, H; Heiser, L; Korkola, JE; Liby, T; Liu, M; Smith, R1
Anderson, A; Chu, YL; Heath, EI; Karrison, T; Martinez, E; Schonhoft, J; Serritella, AV; Shevrin, D; Stadler, WM; Szmulewitz, RZ; Wade, JL1

Trials

1 trial(s) available for mifepristone and mdv 3100

ArticleYear
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 04-14, Volume: 28, Issue:8

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Benzamides; Humans; Male; Mifepristone; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Glucocorticoid

2022

Other Studies

7 other study(ies) available for mifepristone and mdv 3100

ArticleYear
Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
    European journal of medicinal chemistry, 2019, Mar-15, Volume: 166

    Topics: Androgen Receptor Antagonists; Cell Proliferation; Drug Design; Humans; Male; Molecular Docking Simulation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Conformation; Receptors, Androgen; Receptors, Glucocorticoid; RNA, Messenger; Transcription, Genetic; User-Computer Interface

2019
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
    Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23

    Topics: Androgen Receptor Antagonists; Binding Sites; Cell Line; Dimerization; Drug Discovery; Humans; Hydrogen Bonding; Ligands; Molecular Dynamics Simulation; Receptors, Androgen; Transcription, Genetic

2021
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Hormones & cancer, 2014, Volume: 5, Issue:2

    Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoates; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Dexamethasone; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Immediate-Early Proteins; Immunoblotting; Male; Metribolone; Mice; Mice, Nude; Microscopy, Fluorescence; Mifepristone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Androgen; Receptors, Glucocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays

2014
Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping.
    Molecular & cellular proteomics : MCP, 2017, Volume: 16, Issue:8

    Topics: A549 Cells; Benzamides; Co-Repressor Proteins; Dexamethasone; Dihydrotestosterone; DNA-Binding Proteins; Humans; Male; Mifepristone; Nitriles; Nuclear Proteins; Phenylthiohydantoin; Prostatic Neoplasms; Protein Interaction Mapping; Receptors, Androgen; Receptors, Glucocorticoid; Transcription, Genetic

2017
Mifepristone Has Limited Activity to Enhance the
    Anticancer research, 2017, Volume: 37, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Neoplasms; Cell Proliferation; Docetaxel; Hormone Antagonists; Humans; Male; Mice; Mifepristone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017
Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Carcinoma, Ductal; Cell Line, Tumor; Cell Proliferation; Female; Hormone Antagonists; Humans; Male; Middle Aged; Mifepristone; Nitriles; Phenylthiohydantoin; Receptors, Androgen; Receptors, Glucocorticoid; Salivary Gland Neoplasms

2020
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
    Scientific reports, 2020, 12-10, Volume: 10, Issue:1

    Topics: Androgen Antagonists; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; Male; Mifepristone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Receptors, Glucocorticoid; RNA

2020